SyntekaBio, Inc. (226330.KQ)
KOSDAQ · KRW · Healthcare · Health Information Services
₩1,105 (-2.21%) as of
Key statistics
- Market cap
- 26.81B
- Dividend yield
- 0.00%
- 52-week range
- 976.00 – 6,750.00
- Beta
- 0.34
- Revenue (TTM)
- 3.09B
- Profit margin
- 0.00%
- Volume
- 209.06k
About SyntekaBio, Inc.
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was founded in 2009 and is headquartered in Daejeon, South Korea.
- Sector
- Healthcare
- Industry
- Health Information Services
- Headquarters
- Daejeon, South Korea
- Employees
- 45
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.